Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain

Launched by LIFEBRIDGE HEALTH · Jan 20, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two different treatments for people with hip osteoarthritis, which is a condition that causes pain and stiffness in the hip joint. The study compares platelet-rich plasma (PRP) injections, which are made from the patient's own blood, to corticosteroid injections, which are commonly used to reduce inflammation and pain. Researchers want to find out which treatment helps patients experience less pain and improve their ability to move around.

To participate in this trial, individuals should be between 21 and 80 years old and have a specific type of hip osteoarthritis diagnosed through imaging tests. They must also be willing to follow the study procedures and attend all required visits. However, some people may not be eligible, such as those who have had any injections in their hip in the last three months or have certain medical conditions like diabetes. Participants can expect to receive one of the two treatments and will be monitored for their pain and function during the study. This trial is currently recruiting participants, so if you think you might qualify, it could be a great opportunity to help improve treatments for hip osteoarthritis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Provision of signed and dated informed consent form
• • Stated willingness to comply with all study procedures and availability for the duration of the study
• • Male or female, aged 21-80 years
• • Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III Hip osteoarthritis
• • Indicated for a Hip injection to treat Hip OA symptoms
• Exclusion Criteria:
• • Any injections into the target Hip within three months
• • Current overlying skin infection
• • Current or previous diagnosis of "chronic pain"
• • Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)
• • Allergy to any potential ingredients or medications utilized in any of the two groups
• • Treatment with another investigational drug or other intervention for pain
• • Diagnosis of Diabetes Mellitus
• • If female, pregnant or planning to be pregnant within the following 3 months or study duration
• • Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation